CAS 179045-86-4|Basiliximab
Introduction：Basic information about CAS 179045-86-4|Basiliximab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Basiliximab | ||
|---|---|---|---|
| CAS Number | 179045-86-4 | Molecular Weight | / |
| Density | / | Boiling Point | / |
| Molecular Formula | / | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | Unii-9927mt646m |
|---|
Basiliximab BiologicalActivity
| Description | Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation[1]. |
|---|---|
| Related Catalog | Signaling Pathways >>Immunology/Inflammation >>Interleukin RelatedResearch Areas >>Inflammation/Immunology |
| Target | Interleukin-2 receptor[1] |
| In Vitro | Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα[1]. Basiliximab binds only to activated lymphocytes and macrophages/monocytes[3]. Basiliximab does not affect resting T lymphocytes that do not express IL-2Rα[3]. |
| In Vivo | Basiliximab (CHI 621) (0.07 mg/rat; i.v.; once) decreases total placental natural killer cells in reduced uterine perfusion pressure (RUPP) rats[2]. Animal Model: Timed-pregnant Sprague Dawley (SD) rats, reduced uterine perfusion pressure (RUPP) rat model of placental ischemia[2] Dosage: 0.07 mg/rat Administration: IV infusion, once Result: Decreased total placental natural killer cells. Had no effect to lower MAP or improve pup weight and placental weight. |
| References | [1]. McKeage K, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs. 2010 Feb 1;24(1):55-76. [2]. Cunningham M W, et al. The Role of Interleukin‐2 (IL‐2) in Natural Killer Cell (NK) Activation and Hypertension in a Preclinical Rat Model of Preeclampsia. The FASEB Journal, 2018, 32: 911.1-911.1. [3]. Chapman TM, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35. |
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
